CDMO leadership Cerbios-Pharma SA positions itself as a leading CDMO with integrated chemical, biological, and high-potency manufacturing capabilities, offering end-to-end development and manufacturing for APIs, HPAPIs, payloads, ADCs, proteins, and antibodies. This suggests an opportunity to target biotech and pharma companies seeking scalable, single-source manufacturing partners for complex modalities and late-stage programs.

ADC Expertise With Proveo a dedicated ADC division providing payload synthesis, conjugation, CMC, and regulatory support, Cerbios can be pitched to companies advancing antibody-drug conjugates that require integrated, regulated manufacturing from early development to commercial scale, reducing partner oversight and timelines.

HPAPI & Probiotics Cerbios highlights leadership in high-potency active ingredients and a proprietary probiotic strain SF68, suggesting cross-sell opportunities to drug manufacturers needing HPAPI production and to animal health or probiotic dietary supplement players seeking GMP-compliant production and proven strains.

Swiss Precision Rooted in Swiss precision with facilities in Lugano and Couvet and part of the HAS Group, Cerbios offers globally trusted quality and integrated capabilities from clinical development to commercial supply. This can be leveraged to target partners requiring robust regulatory credibility, data integrity, and reliable supply chains for international markets.

Growth Footprint Recent leadership hires in R&D and operations, plus ongoing expansion of high-potency and immune/antiviral capabilities, signal a growth trajectory and capacity readiness for new collaborations, indicating a suitable window for outreach to scale programs and co-development deals.